Daria V. Voronina

Moscow, MOW 123098, Russian Federation

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 17 publications

Structural basis of influenza A virus neutralization by broadly reactive single-domain antibody G2.3 recognizing glycosylated epitope within hemagglutinin stem domain.

Structural basis of influenza A virus neutralization by broadly reactive single-domain antibody G2.3 recognizing glycosylated epitope within hemagglutinin stem domain.

Journal: International journal of biological macromolecules
Published: April 06, 2026

Broadly neutralizing single-domain antibody targeting the spike NTD displays therapeutic efficacy against diverse SARS-CoV-2 variants.

Broadly neutralizing single-domain antibody targeting the spike NTD displays therapeutic efficacy against diverse SARS-CoV-2 variants.

Journal: Frontiers in immunology
Published: January 29, 2026

Single-Dose Intranasal or Intramuscular Administration of Simian Adenovirus-Based H1N1 Vaccine Induces a Robust Humoral Response and Complete Protection in Mice.

Single-Dose Intranasal or Intramuscular Administration of Simian Adenovirus-Based H1N1 Vaccine Induces a Robust Humoral Response and Complete Protection in Mice.

Journal: Viruses
Published: July 11, 2025

Broadly Reactive Nanobody Targeting the H3 Hemagglutinin of the Influenza A Virus.

Broadly Reactive Nanobody Targeting the H3 Hemagglutinin of the Influenza A Virus.

Journal: Acta naturae
Published: January 24, 2024

Cross-Reactive Fc-Fused Single-Domain Antibodies to Hemagglutinin Stem Region Protect Mice from Group 1 Influenza a Virus Infection.

Cross-Reactive Fc-Fused Single-Domain Antibodies to Hemagglutinin Stem Region Protect Mice from Group 1 Influenza a Virus Infection.

Journal: Viruses
Published: October 05, 2022

Single-Domain Antibodies Efficiently Neutralize SARS-CoV-2 Variants of Concern.

Single-Domain Antibodies Efficiently Neutralize SARS-CoV-2 Variants of Concern.

Journal: Frontiers in immunology
Published: November 25, 2021

An open, non-randomised, phase 1/2 trial on the safety, tolerability, and immunogenicity of single-dose vaccine "Sputnik Light" for prevention of coronavirus infection in healthy adults.

An open, non-randomised, phase 1/2 trial on the safety, tolerability, and immunogenicity of single-dose vaccine "Sputnik Light" for prevention of coronavirus infection in healthy adults.

Journal: The Lancet regional health. Europe
Published: November 08, 2021

Development of Neutralizing Nanobodies to the Hemagglutinin Stem Domain of Influenza A Viruses.

Development of Neutralizing Nanobodies to the Hemagglutinin Stem Domain of Influenza A Viruses.

Journal: Acta naturae
Published: June 18, 2021

Nanobodies Are Potential Therapeutic Agents for the Ebola Virus Infection.

Nanobodies Are Potential Therapeutic Agents for the Ebola Virus Infection.

Journal: Acta naturae
Published: June 18, 2021

Review of candidate vaccines for the prevention of Lassa fever

Review of candidate vaccines for the prevention of Lassa fever

Journal: Voprosy virusologii
Published: May 15, 2021

Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia.

Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia.

Journal: Lancet (London, England)
Published: December 31, 2020

Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia.

Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia.

Journal: Lancet (London, England)
Published: August 17, 2020
Showing 1-12 of 17

Last Updated: 09/26/2026